Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Pediatric Disease Priority Review Voucher
Pharma
Fortress sells FDA voucher for $205M after Zycubo approval
The trend of rising FDA voucher prices is continuing as 2026 plays out, with another transaction now valued at $200 million or more.
Eric Sagonowsky
Feb 23, 2026 10:15am
FDA’s rare pediatric voucher program revived by funding bill
Feb 4, 2026 3:12pm
Sentynl, Cyprium score FDA nod for 1st med for Menkes disease
Jan 13, 2026 10:45am
House vote moves FDA's rare PRV program a step closer to revival
Dec 2, 2025 11:22am
Bavarian Nordic's $160M PRV price reflects new realities
Jun 18, 2025 11:47am
Zevra lines up $150M from sale of PRV tied to Miplyffa approval
Feb 27, 2025 9:58am
